Kingson Lin
About
Research
Publications
2024
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Huseman E, Lo A, Fedorova O, Elia J, Gueble S, Lin K, Sundaram R, Oh J, Liu J, Menges F, Rees M, Ronan M, Roth J, Batista V, Crawford J, Pyle A, Bindra R, Herzon S. Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers. Journal Of The American Chemical Society 2024, 146: 18241-18252. PMID: 38815248, DOI: 10.1021/jacs.3c06483.Peer-Reviewed Original ResearchDNA repair capacityDifferential DNA repair capacityDNA interstrand cross-linksRepair capacityInterstrand cross-linksDisplacement of fluorideDNA repairCross-linkingAberrant DNA repairLesionsHealthy tissueBrain cancerRing openingHealthy cellsMGMTSelective chemotherapyGenotoxic agentsTumorChemical DNA modificationsCancerMultistep processRepair
2022
Mechanism-based design of agents that selectively target drug-resistant glioma
Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target drug-resistant glioma. Science 2022, 377: 502-511. PMID: 35901163, PMCID: PMC9502022, DOI: 10.1126/science.abn7570.Peer-Reviewed Original Research
2018
Preparation of Diisopropylammonium Bis(catecholato)cyclohexylsilicate
Lin K, Kelly C, Jouffroy M, Molander* G. Preparation of Diisopropylammonium Bis(catecholato)cyclohexylsilicate. 2018, 16-33. DOI: 10.1002/0471264229.os094.02.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- May 14, 2024
Students and Faculty Mentors Celebrated at Student Research Day
- July 28, 2022
A New Path for Treating Brain Cancer With a Yale-developed Compound
- July 28, 2022Source: Endpoints
By Exploiting the DNA Repair System, Yale Scientists Want to Crack Chemotherapy Resistant Brain Cancer
- April 13, 2022
Kingson Lin, an MD/PhD Student, Receives Paul & Daisy Soros Fellowship for New Americans